Genmab — September 2017
-
God morgen.
-
Her er en opsummering af sammenhæng mellem Exel og Opdivo/Yervoy succes i RCC https://seekingalpha.com/news/3294186-exelixis-9-percent-bristol-myers-successful-study-opdivo-yervoy-rcc?app=1&uprof=45&dr=1#email_link
-
CPH, hvilken betydning har det i forhold til det tekniske?
-
https://www.investing.com/equities/genmab-technical er altid god som hurtigt overblik hvis man er til det tekniske
-
Mere medvind til Opdivo https://seekingalpha.com/news/3294374-bristol-myers-opdivo-outperforms-docetaxel-treatment-resistant-lung-cancer-patients-late?app=1&uprof=45&dr=1#email_link - i solide tumorer fungerer PD-1/PD-L1 fint
-
Here we go: NCT03277105 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/show/NCT03277105 -
"Herman Sanchez @herman_sanchez -
Dr Robert notes that PD1s/PDL1s might need to be discountinued after response. 2 yr? 1 yr??Interesting. Impact to Pharma value? #esmo2017" https://twitter.com/search?f=tweets&vertical=news&q=%23esmo2017&src=tyah -
-
Er tisotumab præsentationen på ESMO nu gået i gang?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind